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Ablation of long-standing persistent atrial fibrillation
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Abstract: Atrial fibrillation (AF) is the most commonly encountered arrhythmia in the clinical setting
affecting nearly 6 million people in United States and the numbers are only expected to rise as the population
continues to age. Broadly it is classified into paroxysmal, persistent and longstanding persistent AF.
Electrical, structural and autonomic remodeling are some of the diverse pathophysiological mechanisms that
contribute to the persistence of AF. Our review article emphasizes particularly on long standing persistent
atrial fibrillation (LSPAF) aspect of the disease which poses a great challenge for electrophysiologists. While
pulmonary vein isolation (PVI) has been established as a successful ablation strategy for paroxysmal AF,
same cannot be said for LSPAF owing to its long duration, complexity of mechanisms, multiple triggers and
substrate sites that are responsible for its perpetuation. The article explains different approaches currently
being adopted to achieve freedom from atrial arrhythmias. These mainly include ablation techniques chiefly
targeting complex fractionated atrial electrograms (CFAE), rotors, linear lesions, scars and even considering
hybrid approaches in a few cases while exploring the role of delayed enhancement magnetic resonance
imaging (deMRI) in the pre-procedural planning to improve the overall short and long term outcomes of
catheter ablation.
Keywords: Long standing persistent atrial fibrillation (LSPAF); catheter ablation; hybrid ablation; complex
fractionated atrial electrograms (CFAE); linear lesion; rotors; pulmonary vein isolations (PVI)
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Introduction
Atrial fibrillation (AF), the most commonly encountered
arrhythmia, is defined as a disorganization in the electrical
impulses of the upper chambers of the heart resulting in
an irregular heartbeat leading to an interrupted blood
flow from atria to the ventricles (1). Currently AF affects
a population of 2.7 to 6.1 million adults in United States.
Almost 2% and 9% of adults below and above the age
of 65, respectively have AF (2). The annual cost of AF is
estimated to be $6 billion (3,4). The economic impact of
this debilitating condition continues to increase with the
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aging population and the ever increasing comorbidities
such as hypertension, diabetes mellitus, heart failure,
chronic kidney disease, ischemic heart disease, obesity and
hyperthyroidism (4).
Classification
For standardization, AF is further categorized into
paroxysmal, persistent or longstanding persistent according
to the guidelines stated by American College of Cardiology,
European Society of Cardiology and American Heart
Association (5). Paroxysmal AF occurs when a patient has
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Figure 1 PVI. A modified posterior view of a left atrial shell
created in a 3D mapping system shows circular radiofrequency

Rhythm Society guidelines, catheter ablation may be
considered for symptomatic LSPAF prior to initiation, or if
refractory/intolerant to, at least one class I or class III antiarrhythmic medication (class IIb indication) (3). The goal
of this review is to discuss the mechanisms that maintain
LSPAF, the various catheter ablation strategies that are
currently being utilized, and their success with short- and
long-term freedom from recurrent atrial arrhythmias. Many
of the studies that will be discussed assess various substrate
modification and trigger ablation strategies in patients
with various stages of AF however most studies combine
the analyses of success in patients with persistent AF and
LSPAF. Given this limitation, we will focus on LSPAF.

lesions (pink, red and green spheres) around ipsilateral pulmonary
vein pairs. The right pulmonary veins are on the right side of the
image and displayed en face, while the left pulmonary veins are
on the left of the image displayed laterally. PVI, pulmonary vein
isolation.

at least two recurrent episodes that self-terminate within
7 days. An AF episode is defined as one that is documented
by electrocardiogram (ECG) monitoring and has a duration
of at least 30 seconds, or if less than 30 seconds, is present
continuously throughout the ECG monitoring tracing.
Paroxysmal AF also includes the patient population in
which cardioversion is performed within 48 hours of onset.
Persistent AF occurs when the arrhythmic episodes endure
beyond 7 days or require cessation with pharmacological
or direct current cardioversion between 48 hours to 7 days
duration. Continuous incidences of AF extending greater
than 12 months are classified as longstanding persistent
(5-7). Silent AF is characterized as an incidental finding on
ECG or rhythm strip in an asymptomatic patient. Once
identified, it can then be additionally characterized into any
of the above listed categories (5). Furthermore, patients
being considered as a candidate for catheter/surgical
ablation for AF should be reclassified and not listed as
permanent AF. This term remains exclusive for patients in
which it is determined not to restore sinus rhythm by any
technique (5).
Goal of review
Successful ablation of long-standing persistent atrial
fibrillation (LSPAF) has been a challenging task for many
electrophysiologists. As per current joint American Heart
Association, American College of Cardiology and Heart
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Mechanism
Early in the clinical process, the pulmonary veins (PV) (5,8)
remain the main site of ectopic foci that initiate AF which
explains a success rate as high as 85% with pulmonary
vein isolation (PVI) catheter ablation (6) (Figure 1). As
AF evolves from paroxysmal to persistent, as a result of
complex underlying electro-structural modifications, the
success rate begins to decrease (5). In 1959, Moe et al.
presented one of the prevailing theories explaining the
concept of AF: the multiple wavelet hypothesis (9). AF
propagates through existing wavelets which in turn are
dependent on diminished conduction, reduced refractory
periods and an enlarged atrial mass. The localized source
hypothesis cultivates the idea of rotors or focal impulses as
the leading etiology of disorganized AF (10,11). In 1994,
Haïssaguerre and colleagues laid down the foundation of
focal mechanisms of AF mainly located in the PV (12).
Later, Ho et al. (13) also identified the cardiac tissue sleeves
in the PV as a possible origin of ectopic foci by shedding
some light on the long forgotten anatomical structures
initially demonstrated by Nathan and Eliakim in 1966 (14).
The main pathophysiological mechanisms giving rise to AF
are electrical and structural alterations in atrial tissue as well
as effects on of the autonomic nervous system (7).
Electrical remodeling
Various medical conditions such as atrial tachyarrhythmias
and heart failure make the atria susceptible to AF.
Normal resting potential is maintained by the large
number of potassium channels (IK1) in atrial cells. The
key mechanisms causing focal atrial arrhythmias are
enhanced automaticity, early afterdepolarization (EAD)
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and delayed afterdepolarizations (DAD) (7). Automaticity,
or spontaneous depolarization, does not occur in normal
atrial myocardial cells (15). Enhanced automaticity occurs
when there is an imbalance of potassium channels (IK1) and
pacemaker current (If) or when there is decreased capacity
of IK1 channel to transport potassium ions (7,15). Excessive
prolongation of action potential duration causes the
development of EAD. It involves early activation of calcium
channel [L-type Ca (I CaL)] during the repolarization phase
allowing inward entry of calcium ions (7,16). Conditions
predisposing to EAD include injured myocardial tissue,
heart failure, electrolytic disturbances, hypoxia, acidosis and
antiarrhythmic agents (15). DADs occur when there is an
abnormal diastolic outflow of calcium from sarcoplasmic
reticulum calcium stores as a response to transmembrane
calcium entry. An excess of diastolic calcium ensues an
exchange of a single calcium ion for three extracellular
sodium ions creating a net positive environment by
transient inward current (Iti) that creates DADs (7,16).
Repetitive DADs lead to focal atrial tachycardias (16).
DADs are usually seen during digitalis toxicity and elevated
catecholaminergic levels (15). Hence electric remodeling
due to underlying atrial conditions can contribute to
progression of AF from a paroxysmal to a persistent form.
Autonomic remodeling
Autonomic remodeling or interplay between the
sympathetic and parasympathetic systems can also generate
ectopic foci within the left atrium (LA) to create and
propagate AF (17). Both animal and human models alike
have shown an association between AF and abnormal
autonomic system function. Numerous autonomic ganglia
are located in the LA with the highest concentration within
5 mm of PV-LA junction. Approximately 30% of ganglionic
cells have both adrenergic and cholinergic properties (18).
Vagal discharge by parasympathetic system and sympathetic
activation leading to a heterogeneous increase in
transmembranous and intracellular calcium and ultimately
the release of norepinephrine, which can trigger focal areas
in the LA and differentially decrease the atrial effective
refractory period across the posterior LA, contribute to the
initiation and preservation of AF (17).
Ablation of the ganglionated plexi overlying the LA
has shown some promise in patients with paroxysmal AF.
Pappone et al. performed circumferential PV ablation in 297
patients with paroxysmal AF; 34.3% of patients underwent
additional vagal denervation (19). At 1 year follow up,
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patients who received additional vagal denervation were
found to have less recurrence of AF compared to their
counterparts. Katritsis et al. randomized 242 patients in
his prospective study to PVI alone, ganglion plexus (GP)
ablation alone or combined PVI-GP ablation (20). At
2 years follow up, freedom from atrial arrhythmia was
74%, 56%, 48% (P=0.004) in the PVI-GP, PVI-alone, and
GP-alone cohort, respectively. Conversely, outcomes with
PVI-GP ablation seem to not be as favorable in patients
with persistent or LSPAF. In 2013, Zheng et al., revealed
at approximately 5 years follow up, the success rate for
surgical PVI-GP ablation was 51.8% for paroxysmal AF,
28.2% for persistent AF, and 28.6% for LSPAF (21). Thus,
the influence of the autonomic nervous system on LSPAF
remains uncertain.
Structure remodeling
There is growing consensus that fibrosis in the atria ranging
from mild to severe can lead to significant advancement in
the disease process of AF. Enhanced expression of collagen I
in the LA can lead to excessive accumulation of collagenous
material in the extracellular space, especially in those with
lone AF (22). Platonov et al. studied the post-mortem atrial
tissue samples obtained from posterior left atrial wall, at the
level of the superior PV, inferior PV, Bachmann’s bundle
and crista terminalis (23). Interestingly, three to five times
greater fibrosis and fatty infiltration was noted compared to
patients with no history of AF, regardless of tissue sampling
site. Furthermore, the extent of fibrosis was higher in the
permanent versus paroxysmal AF cohort. These findings
were similar to Kuppahally et al. who demonstrated
significantly more fibrosis in patients with persistent AF
compared to patients with paroxysmal AF (22%±17% vs.
14%±9%, P=0.04) (24).
Stiles et al. in his small study of 25 patients successfully
demonstrated the role of structural remodeling in AF (25).
Patients with paroxysmal AF had reduced conduction
velocity, longer effective refractory periods and much
lower voltages as a result of abnormal atrial substrate
which promoted progression of AF. Similar conclusions
were also drawn by Teh et al. when they described an
electroanatomic substrate in the LA beyond the focus of the
PV in AF patients without any evidence of structural heart
disease (26). In fact, patients with persistent AF were more
likely to have a greater proportion of low voltage, slower
conduction and increased area of complex signals compared
to paroxysmal AF group. Structural atrial remodeling has
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also been observed at a cellular level in animal models
as a result of rennin-angiotensin system activation (6). A
study in transgenic rats demonstrated that stretching of
the atrial musculature leads to release of angiotensin II and
transforming growth factor-B1which in turn stimulates
interstitial fibrosis and dilatation of atria (27). It remains
unclear if atrial fibrosis is a cause or consequence of AF.
Evidence from numerous studies now helps us
understand some of the fundamental points of structural
remodeling. First, fibrosis helps AF persist and thus
facilitates the transformation from paroxysmal to persistent.
Second, as AF transitions from paroxysmal to persistent, the
location of the substrate for AF gradually shifts away from
the PV which may ultimately guide the ablation approach
for each individual patient.
Typically, patients with hypertension are thought to be
more vulnerable to development of AF given its association
with atrial fibrosis. Uncontrolled systemic hypertension
can lead to LA remodeling due to increased pressure and
volume overload. Not surprisingly, the relationship between
average systolic blood pressure and AF is stronger for
persistent AF compared to paroxysmal AF (28). The atrial
remodeling that is associated with systemic hypertension
has been also characterized by global conduction
slowing, regional conductional delays and increased AF
inducibility (29). Mahnkopf et al. compared LA structural
changes in lone AF patients to the patients with common
conditions like hypertension, diabetes mellitus, congestive
heart failure, stroke and coronary artery disease through
delayed enhancement magnetic resonant imaging (DEMRI) (30). They found that the extent of LA remodeling
was totally independent of the most common comorbidities
and the type of AF. Oakes et al. had a similar observation
in their study of 81 patients demonstrating a high degree
of variability in LA structural remodeling regardless of the
category of AF (31).
Complex fractionated electrograms
Complex fractionated electrograms (CFAE) was first
described in 2004 by Nademanee et al. (32). While there
is much debate as to what qualifies as CFAE, many
investigators define them as continuous atrial activity,
complex fractionated potentials or low voltage electrograms
with a short cycle length of less than 120 milliseconds
over a 10-second period (32-34) (Figure 2). Gerstenfeld
studied the mechanism of CFAE in canine models. He
described wavefront collision as the most common form of
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activation in the region of CFAE (48%) whereas abnormal
conduction through areas of functional block and reentry
phenomenon were responsible for the remainder of CFAE.
The majority of the multiple wavelets were found to be
circulating between posterior LA and entry/exit region of
PV (35). Konings et al. demonstrated that CFAE originate
along the regions of slow conduction, functional block, and
pivot points (33). All three factors facilitate the creation
and persistence of AF. Areas of slow conduction reduce the
wavelength of wavelets and increase their number in atria
while the lines of conduction block disintegrate the wavelets
and the pivot points ensure timely rotation of the wavelets
to prevent their termination at the atrial boundaries. These
abnormal conduction patterns in the atria, if identified, can
serve as a potential target for ablation.
Role of rotors
Rotors are defined as regions of functional reentry
responsible for driving AF (36). Davidenko et al. first
demonstrated the self-sustaining rotating waves, introduced
by delivering a single premature electrical stimulus in a
normal epicardial myocardium (11). Once instigated, this
gives rise to an infinite circulation of self-propagating
waves which can be dissipated only by providing a precisely
timed electrical stimulus. Decades of similar studies have
proven that rotors are a primary phenomenon rather
than a secondary event disseminating spiral waves into
the surrounding the tissue (37). Rotors are enabled by
the ionic and conduction defects at the cellular level and
intermittent areas of fibrosis lead to stabilization of rotors
(36,37). Techniques such as optical mapping, epicardial
contact electrodes with high spatiotemporal resolution
assist in revealing the location of rotors hence making them
potentially amenable for ablation (38,39). However, the
importance of rotors to human AF remains controversial.
More recently, high resolution mapping has shown some
evidence that dissociated fibrillation waves originating
from different directions on the endo-epicardial surface
may act as the main substrate of LSPAF (40). Nevertheless,
additional investigations into underlying mechanism of
propagation of LSPAF are crucial to the development of
successful ablation strategies.
Ablation strategies
PVI has been shown to be a very effective ablation
technique in patients with paroxysmal AF but may not be
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Figure 2 CFAE. Recording of CFAE on a circular mapping catheter (PV 1–2 through 9–10) in the left atrium. Note the high frequency,
rapid activation in PV 1–2, 2–3, 4–5, 5–6, 8–9, 9–10 compared to PV 3–4 and 7–8, as well as coronary sinus (Sd and 3–4). An ablation
catheter (BL) shows CFAE on the proximal (p) pole, but not the distal (d). Also shown are surface ECG leads I and II. CFAE, complex
fractionated atrial electrograms.

as effective by itself in patients with persistent or LSPAF
(41,42). The reason for contrasting success rates is likely
due to the different mechanisms, additional triggers and
substrate that maintain persistent AF. We will now discuss
the adjunctive catheter ablation techniques including
linear lesions, modulation of rotors and focal impulses,
CFAEs, substrate modification including assessing atrial
fibrosis, isolation of left atrial appendage, and surgical based
approach.
Linear lesions
Linear ablation has been utilized to create electrical barriers
that prevent single macro-reentrant wavefronts from
circulating. Swartz et al. initially performed RF ablation
with multiple long linear ablation lines in both atria
deemed as an endocardial replica of the MAZE procedure
(43,44). In 1999, Ernst et al. investigated the safety and
efficacy of biatrial linear ablation versus right atrium (RA)
ablation only which included an isthmus line between the
inferior vena cava (IVC) and tricuspid annulus, an anterior
line between the superior vena cava (SVC) and tricuspid
annulus, and an intercaval line between the ostia of the
IVC and SVC in patients with idiopathic AF (45). Due to
difficulty in creating a left atrial lesion set connecting the
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PV ostia with mitral annulus (MA), 100% recurrence was
noted in the biatrial arm and 94% recurrence in the RA
ablation arm despite a complete linear lesion set in 56% of
patients, concluding that successful linear ablation in the
RA does not prevent AF recurrence. In 2003, Ernst et al.
investigated the efficacy of linear lesions within the LA in
patients with intermittent or chronic symptomatic AF (mean
duration 10±8 years), assessing various strategies including
(I) circular lesion around all PV ostia and a connection to
MA; (II) three linear lesions, including a roof line from
right superior to left superior (LS) PV, ablation from midroof line to anterior MA, and from roof line to posterior
MA; (III) separate encircling lesions around the right and
left PV with linear lesions along the posterior LA wall and
towards the lateral MA; and (IV) encircling lesions as in set
C but without the linear lesions (46). Despite the inability
to achieve conduction block across linear lesions in many
patients, 74% of patients were found to have freedom from
AF at long-term follow up (620±376 days). Not only did
this study reinforce the difficulties in creating long linear
lesions and its propensity for LA macroreentry due to
conduction gaps, but that durable PVI at a minimum is vital
in successful termination of AF.
Jaïs et al. evaluated PVI and cavotricuspid isthmus
(CTI) linear ablation in 100 patients with drug refractory
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LSPV
LAA
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L
MA
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Figure 3 MI Line. A left lateral view of the left atrial shell (grey)
on a 3D mapping system shows ablation lesions (red hexagons)
encircling the LS and LI PV. An additional linear lesion set is seen
connecting the inferior MA to the LIPV lesion set. Also seen is the
LAA. MI, mitral isthmus; LS, left superior; LI, left inferior; PV,
pulmonary veins; MA, mitral annulus; LAA, left atrial appendage.

symptomatic AF and examined its efficacy compared to
100 patients undergoing the same procedure plus linear
mitral isthmus (MI) ablation [lateral MA to left inferior (LI)
PV] (47) (Figure 3). At 1 year follow up, this prospective
non-randomized study revealed 87 patients with MI
ablation in sinus rhythm compared to 69 patients without
(RR for AF recurrence 0.2; 95% CI 0.1–0.4; P<0.001). In
their prospective randomized study including 187 patients,
Fassini et al. also were able to demonstrate that the addition
of MI line compared to PVI alone was more successful in
maintaining sinus rhythm at 1 year follow up (71%±5%
vs. 53%±5%, P<0.01) especially in patients with persistent
AF (48). Feasibility of roofline ablation, linear block
between the right and LS PVs, was initially studied by
Hocini and colleagues in 2005 (49). Ninety patients with
drug refractory paroxysmal AF were divided into two
cohorts: empiric LA roof linear ablation plus PVI and PVI
alone. At 15±4 months follow up, significantly more patients
in the roofline group were arrhythmia-free compared to
those with PVI alone (87% vs. 69%, P=0.04). Roofline
ablation also resulted in an increase in the fibrillatory
cycle length, termination, and subsequent noninducibility
of AF. Wu et al. investigated whether a pure extensive
linear ablation including roofline, MA and CTI without
PVI was associated with better long term outcome in 120
consecutive patients with drug refractory persistent AF (50).
Despite initial successful ablation and conversion to sinus
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rhythm in 62.5%, a median follow up period of 5.1 years
demonstrated that sinus rhythm was maintained without
antiarrhythmic drugs in only 40% of patients.
CFAE
In 2004, Nademanee et al. suggested ablation of AF through
a CFAE-based approach (32). Out of 121 patients enrolled,
76% achieved freedom from AF at 1 year follow up after
one procedure, and 91% after up to two procedures.
Although standard PVI was not performed, most of the
CFAE targeted for ablation originated in PV. While these
initial results were promising, many other investigators
were unable to achieve the same success.
Oral et al. performed CFAE ablation in the LA and
coronary sinus in 100 patients with persistent AF; freedom
from AF was only 33% at 14±7 months follow up (51).
In 2009, Oral et al. then randomized 100 patients with
LSPAF who had failed antral PVI to either have additional
CFAE ablation or cardioversion (50 in each group) (52). At
10±3 months follow up, 36% vs. 34% (P=0.84) were in
sinus rhythm in the cardioversion and CFAE groups,
respectively. The Substrate and Trigger Ablation for
Reduction of Atrial Fibrillation Trial (STAR-AF), a
randomized control multicenter international study in
2010, performed head-to-head comparison of CFAE vs.
PVI vs. PVI plus CFAE in 100 patients with either high
burden paroxysmal AF or persistent AF (53). At 1 year
follow up, 74% of patients in CFAE plus PVI group
remained in sinus rhythm after their first procedure
which increased to 88% after two procedures. In contrast,
successful ablation was reported in only 29% in the CFAEonly cohort which improved to 38% after two procedures.
A meta-analysis comprising of 8 studies and 760 patients
revealed a statistically significant freedom from AF in
CFAE and PVI cohort in persistent AF patients compared
to paroxysmal AF (54). However, in 2015, Providência
et al. performed a meta-analysis of 13 studies involving
1,415 patients and revealed PVI plus CFAE revealed no
superiority over the standard PVI procedure in patients
with paroxysmal or persistent AF patients (55). Estner
et al. also compared CFAE technique to linear ablation in
addition to standard PVI in 116 patients with persistent
AF (56). Both CFAE an d lin ear ablation c o ho rt s
yielded similar results in terms of freedom from atrial
tachyarrhythmias at 1 year follow up (56% vs. 54%, P=0.8).
Nonetheless a greater recurrence of AF was detected in PVI
plus linear ablation group compared to patients assigned to
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PVI and CFAE ablation in whom atrial tachycardia was more
commonly seen.
CFAE ablation beyond PVI does not necessarily enhance
single procedure efficacy in ablating persistent or LSPAF.
The RASTA study demonstrated that the addition of
LA CFAE ablation with PVI was less efficacious to both
PVI plus ablation of non-PV triggers using a stimulation
protocol (standard approach) as well the standard approach
plus empirical ablation of common non-PV AF trigger
sites (MA, fossa ovalis, eustachian ridge, crista terminalis,
and SVC) (57). Interestingly, patients who underwent
repeat ablation for arrhythmia recurrence had at least
1 PV reconnection (≥3 PVs in most subjects). Targeting
these sites alone resulted in excellent long term (80%)
AF control rates suggesting that durable PVI should be
the cornerstone when addressing ablation in persistent
or LSPAF. The STAR-AF II trial compared the approach
of PVI plus CFAE ablation vs. other standard ablation
strategies [PVI plus linear lesions (LA + MI) vs. PVI
alone] in a randomized fashion with patients in persistent
AF (41). The trial concluded that there was no statistically
significant reduction in the rate of recurrent AF with the
addition of linear or CFAE ablation to PVI alone after the
initial blanking period and at 18 months follow up. The
addition of CFAE and linear ablation resulted in longer
procedure time, increased fluoroscopy exposure and slightly
worse procedural adverse effects. Recently, Kim et al.
investigated the combination strategy of combining PVI
and linear lesions followed by CFAE ablation in patients
with LSPAF (58). Interestingly, his prospective randomized
study revealed that additional CFAE ablation resulted in
a numerically (but statistically insignificant) higher AF
recurrence compared to PVI + linear lesions (32.1% vs.
18.5%, P=0.166).
The basis for conflicting data on the CFAE lies in the
fact that CFAE can be a nonspecific indicator of key target
sites (34). All CFAEs are not equivalent, and they can be
created by passive mechanisms that do not play an active
part in propagation of AF (34,59). Further investigation into
distinguishing passive versus active CFAE sites may lead to
more promising outcomes.
Focal impulse and rotor modulation (FIRM)
As mentioned above, rotors and focal impulses have been
suggested by some investigators to be localized sources
that sustain paroxysmal, persistent and LSPAF. FIRM had
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initially shown promise to improve the outcome of AF
ablation in paroxysmal and persistent AF patients with
the intention of eradication of local sources and rotors on
repeat FIRM mapping (60). The Conventional Ablation
for Atrial Fibrillation with or without Focal Impulse and
Rotor Modulation (CONFIRM) trial, a non-randomized
prospective study, revealed that bi-atrial FIRM guided
ablation prior to conventional (PVI) ablation resulted in
an 85% success rate with acute termination of a mixed
population AF vs. 20% with conventional ablation
alone (61). Narayan et al. later published the long term
efficacy of FIRM guided ablation in the 3 years follow up
of the CONFIRM trial: freedom from AF after 890 days
was 77.8% vs. 38.5% in those who received FIRM-guided
plus conventional ablation and conventional PVI alone,
respectively (62).
In 2014, Miller et al. performed a prospective registry
study of mixed AF patients (9% LSPAF) who underwent
FIRM-guided ablation followed by conventional PVI
ablation at 10 experienced ablation centers (63). AF sources
were detected in 100% of patients with each having an
average of 2.3±0.9 rotors or focal sources. Interestingly,
patients with persistent AF had a higher number of atrial
AF sources compared to those with paroxysmal AF,
reinforcing the idea that rotor and focal impulses play
a large role in sustaining non-paroxysmal AF. At 1 year
follow up, freedom from AF as a result of single procedure
was observed in 80.5% (62/77) of patients and 87.5%
of patients who had no prior ablation procedure (35/40;
n=32 persistent/longstanding persistent). However, these
outcomes were not statistically significant (18/23, 78.3%
vs. 44/54, 81.5%, P=0.89) between patients who suffered
from paroxysmal versus persistent AF, respectively. Spitzer
et al. published successful long term outcomes with FIRM
guided combined with conventional ablation (PVI) in
patients with non-paroxysmal AF (83% LSPAF) who had
failed prior conventional ablation (64). At 6 and 12 months
follow-up, 73.2% and 76.9% of patients were free from AF/
AT, respectively. Miller et al. recently reported favorable
long term outcomes noted in their registry of patients who
had undergone FIRM-guided ablation (65). This nonrandomized single center study involved 170 patients with
paroxysmal and non-paroxysmal AF (32% LSPAF) who
underwent FIRM guided ablation followed by PVI (95%
of patients). With regards to patients with LSPAF, the
combination of FIRM-guided and conventional ablation
resulted in acute termination of AF in 19% of patients. At
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1 year follow up, 82% of patients with LSPAF had freedom
from AF without AAD after a single procedure and 57%
with freedom from all atrial arrhythmias.
Despite the promising results of the above mentioned
non-randomized studies of FIRM ablation, they have
not been validated by independent investigators or with
randomized clinical trials. In 2016, the observational
study published by Buch et al. revealed poor long-term
outcomes with FIRM-guided ablation in patients with
paroxysmal and persistent AF; only 37% of patients were
free from AF at 18±7 months follow up (66). Steinberg
et al. also demonstrated low long-term efficacy with FIRMguided ablation in various AF classes in their single-center
observational study (67). FIRM ablation was performed in
43 patients (72% with median of one prior PVI), followed
by redo PVI in 31/43 patients. At 16±10.7 months follow
up, nine (21%) were free from AF. One could argue the
success of the FIRM-guided ablation studies with favorable
outcomes are attributed to adjunctive PVI. As mentioned
multiple times in this review, PVI remains the foundation
to all AF catheter ablations. Given these studies are nonrandomized with no PVI control group, it is difficult
to conclude that FIRM guided ablation is the answer.
Furthermore, the signal processing algorithms used for
FIRM mapping by the only system commercially available
(Topera Solution, Abbott, Menlo Park, CA) has not been
fully revealed its manufacturer. Additionally, the 64-pole
basket catheter generally covers about 50% of the atrial
surface area, calling into question the ability of the system
to identify rotors on the order of a few cm2. As a standalone ablation methodology for non-paroxysmal AF,
FIRM guided ablation alone has not been shown to be
efficacious (68).
Substrate ablation
Recently considerable work has been done to explore atrial
scar sites as a possible arrhythmic substrate responsible
for preservation of AF. As mentioned earlier, AF induces
electrophysiologic and cellular changes which result in its
persistence (“AF begets AF”) (8,69). Delayed enhancement
magnetic resonance imaging (deMRI) has been used to
assess LA fibrosis prior to ablation, and quantify ablation
induced scarring. A single center study revealed that the
degree of circumferential PV scar has been inversely
correlated to procedure success (70). The feasibility of
quantifying atrial fibrosis prior to AF using deMRI was
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investigated in the deMRI-guided Fibrosis Ablation vs.
Conventional Catheter Ablation of Atrial fibrillation
(DECAAF), a multicenter, prospective observational cohort
study. Arrhythmia recurrence was associated with the degree
of left atrial wall fibrosis: for every 1% increase in fibrosis,
HR was 1.06 (95% CI 1.03–1.08; P<0.001) (71).
Catheter ablation based on individual scar distribution
is the emerging approach for treatment of persistent AF. In
2005, Verma and colleagues identified patients with areas
of scar in LA and showed that these patients had higher
incidence of AF recurrence (57%) when compared to
patients with no left atrial scar (19%). Additionally, these
patients had larger LA size, lower ejection fraction, greater
levels of inflammatory markers, and lower success rates with
catheter ablation.
Rolf et al. correlated low voltage areas in LA (<0.5 mV)
to LA scarring and found a higher scar burden amongst
patients with persistent AF (35%) compared to the patients
with paroxysmal AF (10%) (72). They reported a 70%
success rate of ablation with targeting of LA substrate with
low voltage areas in addition to PVI, in comparison to only
26% in patients where PVI was the sole target.
In a recent single center retrospective study, voltageguided ablation therapy was employed to the posterior
wall of LA in addition to PVI versus PVI alone; 80% of
the patients in PVI plus LA posterior wall group were
free from AF in contrast to 57% of the patients with PVI
alone (73). Yamaguchi et al. revealed that low voltage
based substrate modification in addition to PVI is more
efficacious in patients with persistent AF with low voltage
zones (74). Yang and colleagues targeted PV and CTI for
ablation in 86 patients with nonparoxysmal AF; 70% of the
patient population were recognized to have low voltage
areas and hence received additional ablation (75). After 30
months follow up period, 69.8% of the patients were able
to maintain sinus rhythm compared to 51.3% in whom no
further procedures were performed. Studies suggest higher
LA scar burden enable persistence of AF and targeting of
these areas may hold promise of freedom from AF (76).
Another novel ablation strategy called box isolation
of fibrotic areas (BIFA) utilizes electroanatomic voltage
mapping (EAVM) to identify fibrotic LA substrate. This
new concept was initially tested successfully by Kottkamp
et al. in patients with paroxysmal AF who required redo
procedures despite durable PVI. After performing standard
PVI and spontaneous or electrical cardioversion, low
voltage areas were mapped, isolated and ablation lines
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were connected to initial PVI lines. Next, he applied
BIFA plus PVI to patients with non-paroxysmal AF who
had low voltage areas detected by EAVM and achieved a
successful rate of 72.2% single procedure freedom from
AF/AT (77,78). Patients with no detectable low voltage
areas achieved comparable success with PVI alone. This
personalized approach to ablation stresses the importance
of durable PVI as well as EAVM in paroxysmal and nonparoxysmal AF.
Empirical electrical isolation-left atrial appendage
(EEI-LAA)
Non-PV targets such as SVC, ligament of Marshall,
coronary sinus, crista terminalis, and left atrial posterior
wall as a sources for initiating and maintain AF have been
of interest. Another non-PV target and the most common
source of thrombus formation in patients with AF-related
thromboembolism is the LAA (3). In 2010, Di Biase et al.
revealed that LAA firing was observed in 266/987 (27%)
patients with AF referred for redo ablation, with LSPAF
being the most prevalent (58%) (79). EEI-LAA compared
to standard PVI ablation resulted in a 15% versus 74%
(P<0.001) recurrence of AF/AT at 12±3 months follow-up,
respectively. Further stratifying those who had recurrence
and EEI-LAA, LSPAF was noted to have 68% recurrence,
compared to 28% in persistent AF and 4% in paroxysmal
AF which reinforced the difficulty in ablating LSPAF.
The recent randomized study, BELIEF, investigated the
effectiveness of additional empirical electrical LAA isolation
compared to standard PV plus non-PV trigger ablation in
LSPAF (80). At 12 months follow up, 56% of patients who
had received EEI-LAA had freedom of atrial arrhythmias
compared to 28% with standard PV + non-PV ablation.
Even at 24 months follow up with an average of 1.3
procedures, freedom from arrhythmia was noted to be 76%
in those who received EEI-LAA vs. 56% with standard PV
+ non-PV ablation. Repeat ablation was performed in both
cohorts: 27/37 (73%) in EEI-LAA group and 35/63 (56%)
in the standard ablation group. Of note, PV reconnection
was noted to be similar in both groups (11.1% vs. 11.4%,
P=1.0). Despite additional mean radiofrequency ablation
(RFA) time of 16 min, EEI-LAA did not result in a high
procedural complication rate. Isolation of LAA can be
performed electrically or potentially with a mechanical
closure system. In 2015, Lakkireddy et al. studied the impact
of LAA isolation with the percutaneous endo-epicardial
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LARIAT (SentreHeart, Redwood City, CA) procedure
prior to standard PVI ablation in patients with persistent
AF (mean AF duration of 52 months) (81). Freedom from
atrial arrhythmias at 12 months post-ablation was higher
in those who received the additional LARIAT procedure
compared to the standard ablation group (65% vs. 39%;
P=0.002). The prevalence of LAA as a trigger for AF is still
quite low and ablation of this specific source may not apply
to all. A potential issue of LAA-EIA is that the LAA will
no longer contract if isolation is durable, resulting in stasis
and lifelong anticoagulation or requirement for closure.
Another limitation to this approach is the risk of perforation
if ablation is performed within the LAA.
Hybrid approach
Surgical modalities have been utilized to treat patients
with symptomatic drug refractory long standing AF. As per
current guidelines, stand-alone surgical ablation is a Class
IIb recommendation in highly symptomatic AF patients
intolerant of other approaches (3). James Cox’s original
“cut-and-sew” surgical maze procedure (82) which was
developed to treat this specific population now has evolved
into the Cox-maze IV surgery (83). The basis of the maze
procedure is to create lines using RFA, cryoablation, and
surgical incisions in order to partition atrial tissue to prevent
the maintenance of re-entrant wavelets. Soon thereafter the
epicardial-only technique was born, using only RFA alone,
avoiding cryoablation and surgical incisions. This minimally
invasive approach would not require cardiopulmonary
bypass surgery and be able to address the LA using minithoracotomies, thoracoscopy and/or robotics. Similar
to catheter ablation, the success of the epicardial-only
approach is greater with paroxysmal versus persistent AF.
Edgerton et al. demonstrated using a minimally invasive
surgical approach to perform bilateral PV antral isolation
and targeted partial autonomic denervation resulted in
83.7% vs. 56% freedom from AF at 6 months in patients
with paroxysmal AF and persistent/long-standing persistent
AF, respectively (84).
In order to improve its efficacy, the hybrid surgical and
catheter ablation approach was developed. The benefits
of combining endocardial catheter and epicardial surgical
ablation include the formation of transmural lesions
which would be beneficial in the setting of excessive
scar or increased structural remodeling, and addressing
the conduction gaps in lesions caused by epicardial
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88.9% (40/45) of patients at 28 months follow up (88).
Conclusions

Figure 4 Scar created by thoracoscopic epicardial ablation. A
posterior view of the left atrial shell on a 3D mapping system
shows extensive scar (low voltage: red color) across the posterior
wall between the left and right pulmonary veins. An additional
linear lesion set (red discs) is seen across the roof connecting the
left and right superior veins where the surgical ablation tool could
not reach. Purple denotes normal tissue voltage. Border zone is
denoted in blue, yellow and green. MI, mitral isthmus; MA, mitral
annulus; LAA, left atrial appendage; LSPV, left superior pulmonary
veins; LIPV, left inferior pulmonary veins.

ablation. Zembala et al. investigated the safety, feasibility,
effectiveness of the hybrid approach in 70 patients at with
persistent and LSPAF (85). Freedom from arrhythmia
at 6 and 12 months post-procedure was 78.3% and
84.1%, respectively. Geršak et al. reported similar success
with convergent procedure for treatment in 76 patients
with paroxysmal and non-paroxysmal AF and at 4 years
follow up, 81% of patients were in sinus rhythm (86,87).
Potential benefits of convergent procedure include less
radiation exposure, shorter electrophysiology catheterbased procedure, reduction in the likelihood of esophageal
injury that may be caused by endocardial ablation.
However, the procedure is more invasive than purely
endocardial catheter-based ablation strategies (85). Catheter
ablation can be performed immediately after the surgical
thoracoscopic procedure, or months later (Figure 4). A
benefit of performing both procedures during same setting
is no requirement for a second administration of anesthesia
or separate hospitalization. However, allowing enough
time after surgical ablation would allow reconnections
or conduction gap to become more apparent and thus
potentially more successfully ablated. Bisleri et al. utilized
the sequential staged hybrid approach in 45 patients with
LSPAF with catheter ablation occurring at least 1 month
post-surgical ablation. Freedom from AF was noted in
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Ablation of LSPAF is a challenging task; the success of
single procedure or different combination of therapies
is variable and not necessarily reproducible. Is better?
Combining multiple strategies and/or the necessity for
multiple ablation procedures result in potentially longer
fluoroscopy times, increased risk of complications, and
increased risk for creation of substrate for future atrial
arrhythmias. Review of multiple trials and observation
studies have led to the conclusion that durable PVI is
important irrespective of AF classification. The reason why
some patients required redo ablation procedures is often due
to PV reconnection and development of non-PV triggers. A
tailor-made approach utilized for each patient based on type
of AF and presence/location of substrate may offer the best
approach for LSPAF. The role of deMRI to assess for atrial
fibrosis prior to performing catheter ablation continues to
evolve and may allow for more effective prognostication
and pre-procedure planning. Empiric lesion sets appear
to be ineffective and possibly proarrhythmic. As substrate
identification becomes more accurately defined, substrate
modification will likely supplant these empiric approaches.
Additionally, the collaboration between electrophysiologists
and surgeons may offer further evolution of techniques
and technologies to help tear the very difficult LSPAF
population. The safety and efficacy of the above techniques
still needs to be evaluated with prospective randomized
trials in order to gain a better understanding of the various
targets for LSPAF.
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